Lomelí Martínez SM, Martínez Nieto M, Mercado González AE. Tongluo Jiedu as an adjuvant therapy for oral cancer. World J Clin Cases 2025; 13(5): 97909 [DOI: 10.12998/wjcc.v13.i5.97909]
Corresponding Author of This Article
Sarah Monserrat Lomelí Martínez, PhD, Academic Research, Adjunct Associate Professor, Department of Medical and Life Sciences, Centro Universitario de la Ciénega, Universidad de Guadalajara, Av. Universidad 1115, Col. Lindavista, Ocotlán 47810, Mexico. sarah.lomeli@academicos.udg.mx
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 16, 2025; 13(5): 97909 Published online Feb 16, 2025. doi: 10.12998/wjcc.v13.i5.97909
Tongluo Jiedu as an adjuvant therapy for oral cancer
Sarah Monserrat Lomelí Martínez, Melissa Martínez Nieto, Ana Esther Mercado González
Sarah Monserrat Lomelí Martínez, Department of Medical and Life Sciences, Centro Universitario de la Ciénega, Universidad de Guadalajara, Ocotlán 47810, Mexico
Sarah Monserrat Lomelí Martínez, Department of Well-being and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlan 46200, Mexico
Ana Esther Mercado González, Antiguo Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Universidad de Guadalajara, Guadalajara 44280, Mexico
Author contributions: All authors contributed equally to the preparation of this manuscript; Lomelí Martínez SM and Martínez Nieto M the idea; Lomelí Martínez SM, Martínez Nieto M and Mercado González AE did literature search and wrote the preliminary draft; Lomelí Martínez SM and Martínez Nieto M critically reviewed and approved the manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sarah Monserrat Lomelí Martínez, PhD, Academic Research, Adjunct Associate Professor, Department of Medical and Life Sciences, Centro Universitario de la Ciénega, Universidad de Guadalajara, Av. Universidad 1115, Col. Lindavista, Ocotlán 47810, Mexico. sarah.lomeli@academicos.udg.mx
Received: June 12, 2024 Revised: October 11, 2024 Accepted: November 4, 2024 Published online: February 16, 2025 Processing time: 159 Days and 18.7 Hours
Abstract
Oral cancer is one of the malignant neoplasms that present major global health challenge. It is the sixth most prevalent type of cancer in the world, with a high incidence and mortality rate. This letter is a review of the study by Yin et al which was published in the World Journal of Clinical Cases (2024). The study evaluated the effect of Tongluo Jiedu as an adjuvant treatment for oral cancer. Over the years, there has been a continuous search for effective and less invasive treatments for oral cancer. This article emphasizes and discusses various therapeutic options currently available, and it highlights that early intervention and multidisciplinary management are crucial for improving outcomes. Traditional Chinese medicine, particularly Tongluo Jiedu, presents potential complementary approach to conventional oral cancer therapies. Future research on Tongluo Jiedu should be focused on validation of its efficacy and safety through large, well-designed clinical trials, as well as better understanding of the molecular mechanisms involved, and optimization of therapeutic combinations. Additionally, continuous education of health professionals is key to the effective and safe integration of this traditional medicine into clinical practice. Continuous research is essential for optimization of therapeutic strategies and for addressing the challenges presented by this neoplasm.
Core Tip: In this letter, we highlight the article by Yin et al recently published in the World Journal of Clinical Cases (2024), which was focused on the benefits of Tongluo Jiedu as an adjuvant treatment for oral cancer. The study showed that this treatment improved immune function and reduced oxidative stress, thereby aiding recovery of the oral cancer patients. We emphasize the need for early intervention, multidisciplinary management, and the potential of integrating traditional Chinese medicine with conventional therapies.
